Adaptogenics Health Corp. (CSE: ADPT) announced the appointment of Antoun Nabhan, J.D., as President, effective October 1, 2026. Nabhan brings nearly two decades of healthcare investment, corporate finance, and business development experience, having led or advised on more than $2 billion in buy-side healthcare transactions. The appointment signals the company's intent to accelerate asset acquisitions and licensing partnerships as it pursues a proprietary pipeline of peptide and small molecule therapeutics. Investors may be watching this leadership addition as a key step in Adaptogenics' strategic evolution beyond its existing nutraceutical business.

Key Points

  • Adaptogenics Health Corp. (CSE: ADPT) is a Vancouver-based nutraceutical and emerging therapeutics company.
  • Antoun Nabhan, J.D., has been appointed President, effective October 1, 2026.
  • Nabhan has been involved in more than $2 billion in healthcare transactions and led two Nasdaq IPO processes.
  • Investors may watch how the appointment accelerates the company's peptide and small molecule therapeutic pipeline development.

Nabhan's Track Record Across Major Healthcare Transactions

Nabhan's career spans transactional and operating roles at several notable healthcare organisations. He previously served as Senior Vice President at Oaktree Capital Management and currently manages a portfolio of publicly traded healthcare equities at Sagamore Bioventures. His operating roles have included Chief Financial Officer of Establishment Labs and Vice President of Corporate Development at Pear Therapeutics, Raptor Pharmaceuticals, and Capnia, now Soleno Therapeutics. He also held roles at Onyx Pharmaceuticals prior to its acquisition by Amgen and at Raptor Pharmaceuticals prior to its acquisition by Horizon Pharma.

Nasdaq IPO Experience and Pharmaceutical Dealmaking Credentials

The release states that Nabhan led two Nasdaq initial public offering processes across his roles at Establishment Labs and Soleno Therapeutics, formerly Capnia, Inc. He has also co-founded three pharmaceutical development companies, two of which — Convivia and Incellico — have been acquired. His transaction experience includes assets that subsequently received regulatory approval, including Kyprolis, Stivarga, Quinsair, and Somryst. Nabhan holds a J.D. from Harvard Law School and an A.B. from the University of Chicago, where he graduated Phi Beta Kappa.

Nabhan's Mandate at Adaptogenics and Strategic Focus Areas

As President, Nabhan will lead the identification, evaluation, and negotiation of asset acquisitions, licensing partnerships, and strategic collaborations at Adaptogenics. The announcement states he will work alongside Chief Executive Officer Dr. J. David Warren to connect scientific evaluation with transaction structure and capital planning. The company's stated focus is on proprietary peptide and small molecule opportunities targeting metabolic health, muscle preservation, and inflammation, while also maintaining its existing nutraceutical business and evaluating complementary GLP-1 companion product opportunities.